Table 3. Leukocyte Count (103/μL) in Treated Children.
| Treated children, No. | Baseline | After 12 Wk | After 24 Wk | End of Treatment | |
| Group I; IFN + RBV (n = 119) | |||||
| SVR a | 62 | 13.7 ± 1.2 | 12.1 ± 1.1b | 12.1 ± 0.9 c | 12.4 ± 1.2 c |
| Treatment-naïve | 53 | 13.7 ± 1.3 | 12.2 ± 1.1 | 12.1 ± 0.9 c | 12.6± 1.2 |
| Retherapy | 9 | 13.3 ± 0.8 | 11.5 ± 1.3 | 11.6 ± 0.8 | 11.6 ± 1.1 |
| NR a | 57 | 13.7 ± 1.1 | 12.1 ± 1.3 a | 12.6±1.4 c | 13.0±1.2 c |
| Treatment-naïve | 48 | 13.7 ± 0.9 | 12.2 ± 1.2 | 12.6 ± 1.1 c | 13.0 ± 1.1 |
| Retherapy | 9 | 13.8 ± 1.6 | 11.9 ± 1.4 | 12.2 ± 1.2 | 12.4 ± 1.5 |
| group II; Treated With Peg-IFN-α-2b + RBV (n = 51) | |||||
| SVR | 24 | 13.5 ± 1.2 b | 11.6 ± 1.1 b, c | 11.7 ± 1.1 | 12.0 ± 1.5 |
| Treatment-naïve | 15 | 13.7 ± 1.3 | 11.5 ± 1.2 | 11.8 ± 1.0 | 12.0 ± 1.6 |
| Retherapy | 9 | 13.2 ± 1.3 | 11.8 ± 0.9 | 11.4 ± 1.1 | 12.0 ± 1.4 |
| NR | 27 | 14.0 ± 1.0 b | 12.4 ± 1.6 b, c | 12.2 ± 1.5 | 12.6 ± 1.7 |
| Treatment-naïve | 10 | 13.7 ± 1.1 | 12.0 ± 1.2 | 12.6 ± 2.1 | 12.1 ± 1.4 |
| Retherapy | 17 | 14.2 ± 0.9 | 12.7 ± 1.8 | 12.0 ± 1.1 | 12.9 ± 1.8 |
a Abbreviations: nR; non-responders, SVR; Sustained virological response
b Statistically significant difference, P < 0.05 (time dependent in one group)
c Statistically significant difference, P < 0.05 (between groups 1 and 2)